Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP: DMTTF )

0.0560 +0.0049 (+9.59%)
Streaming Delayed Price Updated: 1:33 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,415
Open 0.0542
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0511
Today's Range 0.0542 - 0.0563
52wk Range 0.0468 - 0.3328
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World
U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe. 
Via Benzinga

Performance

YTD
-23.29%
-23.29%
1 Month
-0.18%
-0.18%
3 Month
-16.42%
-16.42%
6 Month
-22.22%
-22.22%
1 Year
-51.56%
-51.56%

More News

Read More
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
From Small Pharma Inc.
Via GlobeNewswire
DMT For Major Depression Shows Remarkable Benefits After Six-Month Trial
Via Benzinga
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
From Small Pharma Inc.
Via GlobeNewswire
EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Via Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
Via Benzinga
Small Pharma Inc: Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable
Via Benzinga
Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference
From Small Pharma Inc.
Via GlobeNewswire
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Via Benzinga
Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial
Via Benzinga
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
From Small Pharma Inc.
Via GlobeNewswire
Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents
Via Benzinga
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings
Via Benzinga
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Via PressReach
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
From Small Pharma Inc.
Via GlobeNewswire
Comparing Psychedelics' Administration Routes: Are Intramuscular Injections More Effective Than Intravenous?
Via Benzinga
First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
From Small Pharma Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.